$WVE
Wave Life Sciences Ltd.

2023 Q4 Form 10-Q Financial Statement

#000095017023061544 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $29.06M $49.21M
YoY Change 2245.12% 17168.07%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $13.66M $13.13M
YoY Change -0.44% 13.1%
% of Gross Profit
Research & Development $34.07M $31.64M
YoY Change 9.64% 14.75%
% of Gross Profit
Depreciation & Amortization $1.081M $1.200M
YoY Change -28.51% -26.7%
% of Gross Profit
Operating Expenses $47.74M $44.77M
YoY Change 6.55% 14.26%
Operating Profit $4.444M
YoY Change -111.42%
Interest Expense $1.844M $1.960M
YoY Change 123.52% 228.86%
% of Operating Profit 44.1%
Other Income/Expense, Net $582.0K $2.131M
YoY Change -300.69% -2129.52%
Pretax Income -$16.26M $6.575M
YoY Change -62.22% -116.86%
Income Tax $0.00 -$677.0K
% Of Pretax Income -10.3%
Net Earnings -$16.26M $7.252M
YoY Change -62.81% -118.59%
Net Earnings / Revenue -55.95% 14.74%
Basic Earnings Per Share $0.07
Diluted Earnings Per Share -$0.15 $0.07
COMMON SHARES
Basic Shares Outstanding 99.05M 98.98M
Diluted Shares Outstanding 107.0M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $200.4M $139.9M
YoY Change 126.39% 14.67%
Cash & Equivalents $200.4M $139.9M
Short-Term Investments
Other Short-Term Assets $4.024M $4.116M
YoY Change 90.89% 104.07%
Inventory
Prepaid Expenses $9.912M $7.514M
Receivables $21.09M $7.000M
Other Receivables $0.00 $0.00
Total Short-Term Assets $235.4M $158.6M
YoY Change 138.87% 20.65%
LONG-TERM ASSETS
Property, Plant & Equipment $13.08M $13.77M
YoY Change -24.3% -25.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.855M $3.800M
YoY Change 3.57% 2.76%
Total Long-Term Assets $39.58M $41.35M
YoY Change -17.29% -17.44%
TOTAL ASSETS
Total Short-Term Assets $235.4M $158.6M
Total Long-Term Assets $39.58M $41.35M
Total Assets $274.9M $199.9M
YoY Change 87.82% 10.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.84M $12.61M
YoY Change -24.1% -20.87%
Accrued Expenses $1.768M $3.080M
YoY Change -49.72% 61.51%
Deferred Revenue $150.1M $68.25M
YoY Change 375.5% 111.04%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $186.4M $99.98M
YoY Change 160.68% 55.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $41.01M $132.6M
YoY Change 21481.58% 16.42%
Total Long-Term Liabilities $41.01M $132.6M
YoY Change -63.42% 16.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $186.4M $99.98M
Total Long-Term Liabilities $41.01M $132.6M
Total Liabilities $227.4M $232.5M
YoY Change 23.88% 30.52%
SHAREHOLDERS EQUITY
Retained Earnings -$1.025B -$1.009B
YoY Change 5.95% 9.2%
Common Stock $935.4M $841.4M
YoY Change 16.51% 4.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $39.63M -$40.49M
YoY Change
Total Liabilities & Shareholders Equity $274.9M $199.9M
YoY Change 87.82% 10.14%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$16.26M $7.252M
YoY Change -62.81% -118.59%
Depreciation, Depletion And Amortization $1.081M $1.200M
YoY Change -28.51% -26.7%
Cash From Operating Activities -$33.24M -$34.46M
YoY Change -0.6% 34.37%
INVESTING ACTIVITIES
Capital Expenditures $356.0K $200.0K
YoY Change 74.51% -143.76%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities -$356.0K -$200.0K
YoY Change -101.43% -60.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 93.96M 1.670M
YoY Change 170740.0% 9723.53%
NET CHANGE
Cash From Operating Activities -33.24M -34.46M
Cash From Investing Activities -356.0K -200.0K
Cash From Financing Activities 93.96M 1.670M
Net Change In Cash 60.37M -32.99M
YoY Change -806.46% 26.25%
FREE CASH FLOW
Cash From Operating Activities -$33.24M -$34.46M
Capital Expenditures $356.0K $200.0K
Free Cash Flow -$33.60M -$34.66M
YoY Change -0.15% 37.6%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001631574
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37627
dei Entity Registrant Name
EntityRegistrantName
WAVE LIFE SCIENCES LTD.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
U0
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1356880
dei Entity Address Address Line1
EntityAddressAddressLine1
7 Straits View #12-00
dei Entity Address Address Line2
EntityAddressAddressLine2
Marina One
dei Entity Address City Or Town
EntityAddressCityOrTown
East Tower
dei Entity Address Country
EntityAddressCountry
SG
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
018936
dei City Area Code
CityAreaCode
+65
dei Local Phone Number
LocalPhoneNumber
6236 3388
dei Security12b Title
Security12bTitle
$0 Par Value Ordinary Shares
dei Trading Symbol
TradingSymbol
WVE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
99053902
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
139942000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
88497000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7000000
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
7514000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
7932000
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
4116000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2108000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
158572000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
98537000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
41596000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
37846000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13770000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17284000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23738000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26843000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3683000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3660000
CY2023Q3 us-gaap Other Assets
OtherAssets
155000
CY2022Q4 us-gaap Other Assets
OtherAssets
62000
CY2023Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
41346000
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
47849000
CY2023Q3 us-gaap Assets
Assets
199918000
CY2022Q4 us-gaap Assets
Assets
146386000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
12608000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
16915000
CY2023Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
12624000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
17552000
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
68251000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
31558000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6497000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5496000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
99980000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
71521000
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
105380000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
79774000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
27170000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
32118000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
190000
CY2023Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
132550000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
112082000
CY2023Q3 us-gaap Liabilities
Liabilities
232530000
CY2022Q4 us-gaap Liabilities
Liabilities
183603000
CY2023Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
3901348
CY2023Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
3901348
CY2023Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
3901348
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
3901348
CY2023Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
7874000
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
7874000
CY2023Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2022Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
99011901
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
99011901
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
86924643
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86924643
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
841405000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
802833000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
126885000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
119442000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-182000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-29000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1008594000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-967337000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-40486000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-45091000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
199918000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
146386000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
49214000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
285000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
84249000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2410000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31642000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27575000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
95935000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
84778000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13128000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11609000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
37628000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
36789000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
44770000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
39184000
us-gaap Operating Expenses
OperatingExpenses
133563000
us-gaap Operating Expenses
OperatingExpenses
121567000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
4444000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-38899000
us-gaap Operating Income Loss
OperatingIncomeLoss
-49314000
us-gaap Operating Income Loss
OperatingIncomeLoss
-119157000
CY2023Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
1960000
CY2022Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
596000
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
6084000
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
746000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
171000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-701000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1296000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
297000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2131000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-105000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7380000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1043000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
6575000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39004000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-41934000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-118114000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-677000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-677000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
7252000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-39004000
us-gaap Net Income Loss
NetIncomeLoss
-41257000
us-gaap Net Income Loss
NetIncomeLoss
-118114000
CY2023Q3 us-gaap Participating Securities Distributed And Undistributed Earnings Loss Basic
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
-257000
CY2023Q3 wve Net Income Loss Available To Common Stockholders
NetIncomeLossAvailableToCommonStockholders
6995000
CY2022Q3 wve Net Income Loss Available To Common Stockholders
NetIncomeLossAvailableToCommonStockholders
-39004000
wve Net Income Loss Available To Common Stockholders
NetIncomeLossAvailableToCommonStockholders
-41257000
wve Net Income Loss Available To Common Stockholders
NetIncomeLossAvailableToCommonStockholders
-118114000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.6
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106025063
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
93900484
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
104529266
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73754417
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.6
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
106975231
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
93900484
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
104529266
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73754417
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
7252000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-39004000
us-gaap Net Income Loss
NetIncomeLoss
-41257000
us-gaap Net Income Loss
NetIncomeLoss
-118114000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-32000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-76000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-153000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-304000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
7220000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39080000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41410000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-118418000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
32498000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
3971000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
37000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
174000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-86000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-37814000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-53000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
51220000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
14268000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
6950000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-142000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-41296000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
30947000
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
3366000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
50000
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
198000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-76000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-39004000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-4519000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-45091000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
34623000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
2750000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
429000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-21000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-27405000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-34714000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1704000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
2409000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
85000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-100000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-21104000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-51720000
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
2284000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
35000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
319000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-32000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
7252000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-40486000
us-gaap Profit Loss
ProfitLoss
-41257000
us-gaap Profit Loss
ProfitLoss
-118114000
wve Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
3105000
wve Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
2557000
us-gaap Depreciation
Depreciation
3919000
us-gaap Depreciation
Depreciation
5062000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7443000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14287000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7000000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-418000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
835000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2101000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-3503000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3953000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
8337000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-4928000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3805000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
62299000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2006000
wve Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-3947000
wve Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-3327000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-190000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
13808000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-94341000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
759000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1157000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
106000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
75044000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
50000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-759000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-26095000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
34623000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
51235000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
14272000
wve Proceeds From Issuance Of Ordinary Shares Pursuant To At The Market Equity Program Net
ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet
3080000
wve Proceeds From Issuance Of Ordinary Shares Pursuant To At The Market Equity Program Net
ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet
1167000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
121000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
87000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
748000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
372000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
38572000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
67133000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-153000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-304000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
51468000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-53607000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
92157000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
154215000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
143625000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
100608000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
12006000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
139900000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of the Company’s financial statements and related disclosures requires the Company to make estimates and assumptions that affect the reported amount of assets, liabilities, revenue, costs and expenses and related disclosures. Management considers many factors in selecting appropriate financial accounting policies and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. The Company believes that its revenue recognition policy, particularly (a) assessing the number of performance obligations; (b) determining the transaction price; (c) allocating the transaction price to the performance obligations in the contract; and (d) determining the pattern over which performance obligations are satisfied, including estimates to complete performance obligations, and the assumptions and estimates used in the Company’s analysis of contracts with contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”) to estimate the contract expense, involve a greater degree of judgment, and therefore the Company considers them to be its critical accounting policies. The Company evaluates its estimates and assumptions on an ongoing basis. The Company’s actual results may differ from these estimates under different assumptions and conditions.</span></p>
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8457000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12287000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3080000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3516000
CY2023Q3 wve Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
1087000
CY2022Q4 wve Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
1749000
CY2023Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
12624000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
17552000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14238590
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9732711
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
633283
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
999771
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
7252000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-39004000
us-gaap Net Income Loss
NetIncomeLoss
-41257000
us-gaap Net Income Loss
NetIncomeLoss
-118114000
CY2023Q3 us-gaap Participating Securities Distributed And Undistributed Earnings Loss Basic
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
-257000
CY2023Q3 wve Net Income Loss Available To Common Stockholders
NetIncomeLossAvailableToCommonStockholders
6995000
CY2022Q3 wve Net Income Loss Available To Common Stockholders
NetIncomeLossAvailableToCommonStockholders
-39004000
wve Net Income Loss Available To Common Stockholders
NetIncomeLossAvailableToCommonStockholders
-41257000
wve Net Income Loss Available To Common Stockholders
NetIncomeLossAvailableToCommonStockholders
-118114000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106025063
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
93900484
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
104529266
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73754417
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
950168
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
106975231
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
93900484
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
104529266
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73754417
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.6
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.6
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0

Files In Submission

Name View Source Status
0000950170-23-061544-index-headers.html Edgar Link pending
0000950170-23-061544-index.html Edgar Link pending
0000950170-23-061544.txt Edgar Link pending
0000950170-23-061544-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img56423468_0.jpg Edgar Link pending
img56423468_1.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
wve-20230930.htm Edgar Link pending
wve-20230930.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
wve-20230930_cal.xml Edgar Link unprocessable
wve-20230930_def.xml Edgar Link unprocessable
wve-ex10_1.htm Edgar Link pending
wve-ex31_1.htm Edgar Link pending
wve-ex31_2.htm Edgar Link pending
wve-ex32.htm Edgar Link pending
wve-20230930_lab.xml Edgar Link unprocessable
wve-20230930_pre.xml Edgar Link unprocessable
wve-20230930_htm.xml Edgar Link completed